Innocent Valea

Toussaint Rouamba

This project seeks to generate robust evidence on the safety, tolerability, and efficacy of antimalarials for the treatment of uncomplicated P. falciparum malaria in the first trimester of pregnancy. Additionally, it aims to translate research findings into treatment guidelines, promote their implementation in clinical practice, and ultimately ensure that healthcare providers and pregnant women have access to optimal treatment options that prevent or minimise the impact of malaria infections during early pregnancy.
The SAFIRE Consortium is a multi-disciplinary initiative aimed at developing a robust, context-specific clinical trial with the potential to generate meaningful and generalizable results to help fill knowledge gaps and increase access to antimalarial treatment, thereby improving maternal health and pregnancy outcomes in malaria-endemic regions where resources are limited. The project comprises six work packages including coordination (WP1), scientific project management (WP2), clinical trial (WP3), formative and implementation research and economic evaluation (WP4), communication, dissemination and exploitation (WP5), and capacity building and training (WP6).

EDCTP-3 through the European Union

July 2024

April 2025